首页
热心肠日报
文献库
产业库
榜单
关于日报
《肠·道》演讲
往期精彩
《肠·道》2024
《肠·道》2023
《肠·道》2022
《肠·道》2021
《肠·道》2020
《肠·道》2019
《肠·道》2018
《肠·道》2017
关于《肠·道》
肠道大会
热心肠大会
热心肠智库
智库专家
专家动态
智库新闻
关于智库
奖学金
年度人物奖
更多
HOPE
会议信息
科学与艺术
学术专刊
R·AI
周刊
热心肠先生
研究院动态
关于我们
搜索
登录
关闭
手机邮箱登录
扫码登录
微信扫描二维码快捷登录
验证成功,将在
3
秒钟后跳转
已超时,请
重试
关闭
二维码登录
手机登录
邮箱登录
+86
+1
+852
+886
+81
+65
+61
+44
获取验证码
登录 / 注册
关闭
二维码登录
手机登录
邮箱登录
获取验证码
登录 / 注册
热心肠智库
专家文章 | 陈东风
2023
CA
Potential candidates for liver resection in liver-confined advanced HCC: a Chinese multicenter observational study
FRONT ONCOL, 10.3389/fonc.2023.1170923
CA
Identify optimal HAP series scores for unresectable HCC patients undergoing TACE plus sorafenib: A Chinese multicenter observational study
FRONT ONCOL, 10.3389/fonc.2022.983554
CA
The role of Th17 cells in inflammatory bowel disease and the research progress
Front Immunol, 10.3389/fimmu.2022.1055914
2022
CA
High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial
THER ADV GASTROENTER, 10.1177/17562848221145566
CA
High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial
THER ADV GASTROENTER, 10.1177/17562848221145566
CA
High-dose dual therapy versus culture-based susceptibility-guided therapy as a rescue regimen for Helicobacter pylori infection: a randomized controlled trial
THER ADV GASTROENTER, 10.1177/17562848221145566
CA
Clinical study on sequential treatment of severe diarrhea irritable bowel syndrome with precision probiotic strains transplantation capsules, fecal microbiota transplantation capsules and live combined bacillus subtilis and enterococcus faecium capsules
FCIMB, 10.3389/fcimb.2022.1025889
2021
CA
Fecal Microbiota Transplantation Relieves Gastrointestinal and Autism Symptoms by Improving the Gut Microbiota in an Open-Label Study
FCIMB, 10.3389/fcimb.2021.759435
点击查看热心肠日报解读
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
RFWD3 Participates in the Occurrence and Development of Colorectal Cancer via E2F1 Transcriptional Regulation of BIRC5
Front Cell Dev Biol, 10.3389/fcell.2021.675356
CA
Clinical course and outcomes of COVID-19 patients with a history of cerebrovascular disease: a retrospective study in Wuhan
Ann Transl Med, 10.21037/atm-21-2237
2020
CA
SHARPIN stabilizes β-catenin through a linear ubiquitination-independent manner to support gastric tumorigenesis
Gastric Cancer, 10.1007/s10120-020-01138-5